Olaparib Prolongs rPFS in Metastatic Castration-Resistant Prostate Cancer

Adding olaparib to first-line abiraterone improved radiographic progression-free survival in metastatic castration-resistant prostate cancer.

Related Keywords

Montreal ,Quebec ,Canada ,Fred Saad ,Astrazeneca ,University Of Montreal Hospital Center ,Merck Sharp Dohme Corp ,Cancers Symposium ,Cancer Therapy Advisor ,Montreal Hospital Center ,Merck Sharp ,